BioWorld Asia

Jan. 30, 2002

UroGene, Pierre Fabre Enter 3-Year Cancer Collaboration

PARIS UroGene SA entered into a three-year research collaboration with Pierre Fabre M dicament to discover and develop new active compounds to treat prostate cancer against a validated biological target identified by UroGene. (BioWorld International) Read More

Symphogen Raises US$15M To Develop Polyclonal Antibodies

Peptide Study Yields Insights Into Autoimmune Disease Mechanisms

Synt:em, Baxter Collaborate On Peptide Mimetics Of MAbs

UK Creating Centers To Help Capitalize On Genetics Progress

Galapagos, Exelixis Collaborate To Analyze Functions Of Genes

Biogen Paying Schering $20M Or More Over MS Drug Patents

BIA Calls For More Support To Deal With Animal Rights Activists

Dutch Biotech Association Seeks Clearer Signals From Politicians

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 24, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...